Autor: |
Van Der Horst-Schrivers, ANA, Jager, PL, Boezen, HM, Schouten, JP, Kema, IP, Links, TP |
Přispěvatelé: |
Guided Treatment in Optimal Selected Cancer Patients (GUTS), Life Course Epidemiology (LCE), Groningen Research Institute for Asthma and COPD (GRIAC), Lifestyle Medicine (LM), Damage and Repair in Cancer Development and Cancer Treatment (DARE) |
Jazyk: |
angličtina |
Rok vydání: |
2006 |
Předmět: |
|
Zdroj: |
Anticancer Research, 26(2B), 1599-1604. INT INST ANTICANCER RESEARCH |
ISSN: |
0250-7005 |
Popis: |
BACKGROUND: Recommendations on the use of I-123 metaiodobenzylguanidine (MIBG) scintigraphy in localising phaeochromocytomas vary. The accuracy of I-123 MIBG scintigraphy was determined by evaluating our own I-123 MIBG scans and performing a meta-analysis. MATERIALS AND METHODS: Between January 1992 and May 2002, the I-123 MIBG scans of consecutive patients suspected of a phaeochromocytoma were re-evaluated. For the meta-analysis, studies with more than 5 I-123 MIBG scans were selected. RESULTS: Thirty patients were evaluated. The sensitivity in our own population was 92% and the specificity was 100%. Twelve articles were selected for our meta-analysis. The overall sensitivity and specificity were 96% and 100%, respectively. The sensitivity and specificity for tumours in the adrenal gland was 98% for both. For tumours located outside the adrenal gland, the sensitivity was 98% and the sensitivity for malignancies was 79%. CONCLUSION: 1-123 MIBG scintigraphy has an excellent sensitivity and specificity in localising phaeochromocytomas, except for malignant tumours. 1-123 MIBG scintigraphy is superior in localising tumours outside the adrenal gland. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|